Confirmation of 5p12 as a susceptibility locus for progesterone-receptor- positive, lower grade breast cancer

Roger L. Milne, Ellen L. Goode, Montserrat García-Closas, Fergus J. Couch, Gianluca Severi, Rebecca Hein, Zachary Fredericksen, Núria Malats, M. Pilar Zamora, Jose Ignacio Arias Pérez, Javier Benítez, Thilo Dörk, Peter Schürmann, Johann H. Karstens, Peter Hillemanns, Angela Cox, Ian W. Brock, Graeme Elliot, Simon S. Cross, Sheila SealClare Turnbull, Anthony Renwick, Nazneen Rahman, Chen Yang Shen, Jyh Cherng Yu, Chiun Sheng Huang, Ming Feng Hou, Børge G. Nordestgaard, Stig E. Bojesen, Charlotte Lanng, Grethe Grenaker Alnæs, Vessela Kristensen, Anne Lise Børrensen-Dale, John L. Hopper, Gillian S. Dite, Carmel Apicella, Melissa C. Southey, Diether Lambrechts, Betül T. Yesilyurt, Giuseppe Floris, Karin Leunen, Suleeporn Sangrajrang, Valerie Gaborieau, Paul Brennan, James McKay, Jenny Chang-Claude, Shan Wang-Gohrke, Paolo Radice, Paolo Peterlongo, Siranoush Manoukian, Monica Barile, Graham G. Giles, Laura Baglietto, Esther M. John, Alexander Miron, Stephen J. Chanock, Jolanta Lissowska, Mark E. Sherman, Jonine D. Figueroa, Natalia V. Bogdanova, Natalia N. Antonenkova, Iosif V. Zalutsky, Yuri I. Rogov, Peter A. Fasching, Christian M. Bayer, Arif B. Ekici, Matthias W. Beckmann, Hermann Brenner, Heiko Müller, Volker Arndt, Christa Stegmaier, Irene L. Andrulis, Julia A. Knight, Gord Glendon, Anna Marie Mulligan, Arto Mannermaa, Vesa Kataja, Veli Matti Kosma, Jaana M. Hartikainen, Alfons Meindl, Joerg Heil, Claus R. Bartram, Rita K. Schmutzler, Gilles D. Thomas, Robert N. Hoover, Olivia Fletcher, Lorna J. Gibson, Isabel Dos Santos Silva, Julian Peto, Stefan Nickels, Dieter Flesch-Janys, Hoda Anton-Culver, Argyrios Ziogas, Elinor Sawyer, Ian Tomlinson, Michael Kerin, Nicola Miller, Marjanka K. Schmidt, Annegien Broeks, Laura J. Van't Veer, Rob A.E.M. Tollenaar, Paul D.P. Pharoah, Alison M. Dunning, Karen A. Pooley, Frederik Marme, Andreas Schneeweiss, Christof Sohn, Barbara Burwinkel, Anna Jakubowska, Jan Lubinski, Katarzyna Jaworska, Katarzyna Durda, Daehee Kang, Keun Young Yoo, Dong Young Noh, Sei Hyun Ahn, David J. Hunter, Susan E. Hankinson, Peter Kraft, Sara Lindstrom, Xiaoqing Chen, Jonathan Beesley, Ute Hamann, Volker Harth, Christina Justenhoven, Robert Winqvist, Katri Pylkäs, Arja Jukkola-Vuorinen, Mervi Grip, Maartje Hooning, Antoinette Hollestelle, Rogier A. Oldenburg, Madeleine Tilanus-Linthorst, Elza Khusnutdinova, Marina Bermisheva, Darya Prokofieva, Albina Farahtdinova, Janet E. Olson, Xianshu Wang, Manjeet K. Humphreys, Qin Wang, Georgia Chenevix-Trench, Douglas F. Easton

Research output: Contribution to journalArticle

Abstract

Background: The single-nucleotide polymorphism (SNP) 5p12-rs10941679 has been found to be associated with risk of breast cancer, particularly estrogen receptor (ER)-positive disease. We aimed to further explore this association overall, and by tumor histopathology, in the Breast Cancer Association Consortium. Methods: Data were combined from 37 studies, including 40,972 invasive cases, 1,398 cases of ductal carcinoma in situ (DCIS), and 46,334 controls, all of white European ancestry, as well as 3,007 invasive cases and 2,337 controls of Asian ancestry. Associations overall and by tumor invasiveness and histopathology were assessed using logistic regression. Results: For white Europeans, the per-allele OR associated with 5p12-rs10941679 was 1.11 (95% CI = 1.08-1.14, P = 7 × 10-18) for invasive breast cancer and 1.10 (95% CI = 1.01-1.21, P = 0.03) for DCIS. For Asian women, the estimated OR for invasive disease was similar (OR = 1.07, 95%CI = 0.99-1.15, P = 0.09). Further analyses suggested that the association in white Europeans was largely limited to progesterone receptor (PR)- positive disease (per-allele OR = 1.16, 95% CI = 1.12-1.20, P = 1 × 10-18 vs. OR = 1.03, 95% CI = 0.99-1.07, P = 0.2 for PR-negative disease; Pheterogeneity = 2 × 10 -7); heterogeneity by ER status was not observed (P= 0.2) once PR status was accounted for. The association was also stronger for lower grade tumors [per-allele OR (95% CI) = 1.20 (1.14-1.25), 1.13 (1.09-1.16), and 1.04 (0.99-1.08) for grade 1, 2, and 3/4, respectively; Ptrend = 5 × 10 -7]. Conclusion: 5p12 is a breast cancer susceptibility locus for PR-positive, lower grade breast cancer. Impact: Multicenter fine-mapping studies of this region are needed as a first step to identifying the causal variant or variants.

Original languageEnglish (US)
Pages (from-to)2222-2231
Number of pages10
JournalCancer Epidemiology Biomarkers and Prevention
Volume20
Issue number10
DOIs
StatePublished - Oct 2011

    Fingerprint

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Milne, R. L., Goode, E. L., García-Closas, M., Couch, F. J., Severi, G., Hein, R., Fredericksen, Z., Malats, N., Zamora, M. P., Pérez, J. I. A., Benítez, J., Dörk, T., Schürmann, P., Karstens, J. H., Hillemanns, P., Cox, A., Brock, I. W., Elliot, G., Cross, S. S., ... Easton, D. F. (2011). Confirmation of 5p12 as a susceptibility locus for progesterone-receptor- positive, lower grade breast cancer. Cancer Epidemiology Biomarkers and Prevention, 20(10), 2222-2231. https://doi.org/10.1158/1055-9965.EPI-11-0569